Tech Company Inital Public Offerings
TransMedics IPO
Based in Andover, TransMedics is now a public company.
Transaction Overview
Company Name
Announced On
5/2/2019
Transaction Type
IPO
Amount
$91,200,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $25.0 million to support commercialization of the OCS Lung and, if approved, the OCS Heart in the United States; approximately $20.0 million to fund research and development to design and manufacture the next generation of OCS technology; approximately $15.0 million for clinical trial expenditures, including those relating to our pre- and post-market clinical trials, including our TOP Registry, our OCS Liver PROTECT Trial and the use of the OCS Heart for DCD donor hearts; and the balance for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
200 Minuteman Rd. 302
Andover, MA 01810
USA
Andover, MA 01810
USA
Phone
Website
Email Address
Overview
TransMedics (Nasdaq: TMDX) has developed a revolutionary new system that enables living organ transplants.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Waleed Hassanein
Chief Financial Officer
Stephen Gordon
Chief Medical Officer
Tamer Khayal
Vice President
Jacqueline Sneve
VP - Engineering
John Sullivan
VP - Operations
John Carey
VP - Regulatory Affairs
Miriam Provost
Browse more venture capital transactions:
Prev: 5/2/2019: Forto venture capital transaction
Next: 5/2/2019: TerraClear venture capital transaction
Share this article
About Database of VC Transactions
We document tech company VC transactions. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs